Ty Kayam is Of Counsel in the Seattle office of Wilson Sonsini Goodrich & Rosati, where she advises companies and investors working at the intersection of healthcare, artificial intelligence, software, and data.
Ty’s practice is informed by direct experience working with generative AI, wearables, robotics, and other emerging technologies that do not fit neatly within existing regulatory frameworks. Ty counsels clients on regulatory matters across the lifecycle of health technology products, including those that arise in developing, deploying, financing, and acquiring these products. Ty also advises on health data exchange, interoperability, and information blocking, including related obligations that arise when products connect to EHRs, health information networks, and other connected devices or systems.
Prior to joining the firm, Ty served as the first attorney in the FDA’s Digital Health Center of Excellence. Her work addressed legal and policy questions involving digital health, software, AI-enabled medical technologies, lifecycle regulation, predetermined change control plans, and pre- and post-market issues for novel software-enabled products. She has also worked across FDA, other federal agencies, and international partners on regulatory alignment for digital health and AI.
Earlier, Ty was senior corporate counsel at Microsoft, where she advised product and business teams developing and commercializing health AI and digital health technologies. She counseled teams on product development, enterprise deployments, data licensing, strategic partnerships, and global regulatory and policy strategy for emerging health technology products.
Ty has taught health technology law as an adjunct professor at Seattle University School of Law and has guest lectured at the University of Ottawa, Florida University, American University, and other institutions. Her background in science, public policy, and technology informs her work with companies developing health products in regulated markets.
Ty is fluent in Telugu.
Ty Kayam is Of Counsel in the Seattle office of Wilson Sonsini Goodrich & Rosati, where she advises companies and investors working at the intersection of healthcare, artificial intelligence, software, and data.
Ty’s practice is informed by direct experience working with generative AI, wearables, robotics, and other emerging technologies that do not fit neatly within existing regulatory frameworks. Ty counsels clients on regulatory matters across the lifecycle of health technology products, including those that arise in developing, deploying, financing, and acquiring these products. Ty also advises on health data exchange, interoperability, and information blocking, including related obligations that arise when products connect to EHRs, health information networks, and other connected devices or systems.
Prior to joining the firm, Ty served as the first attorney in the FDA’s Digital Health Center of Excellence. Her work addressed legal and policy questions involving digital health, software, AI-enabled medical technologies, lifecycle regulation, predetermined change control plans, and pre- and post-market issues for novel software-enabled products. She has also worked across FDA, other federal agencies, and international partners on regulatory alignment for digital health and AI.
Earlier, Ty was senior corporate counsel at Microsoft, where she advised product and business teams developing and commercializing health AI and digital health technologies. She counseled teams on product development, enterprise deployments, data licensing, strategic partnerships, and global regulatory and policy strategy for emerging health technology products.
Ty has taught health technology law as an adjunct professor at Seattle University School of Law and has guest lectured at the University of Ottawa, Florida University, American University, and other institutions. Her background in science, public policy, and technology informs her work with companies developing health products in regulated markets.
Ty is fluent in Telugu.
Editor, Northeastern Law Review; Health Law Moot Court Program
Editor, Northeastern Law Review; Health Law Moot Court Program